The Effect of Tennis Ball on Balance and Quality of Life in Cancer Patients With Neuropathy.
Launched by SELCUK UNIVERSITY · Apr 16, 2024
Trial Information
Current as of November 13, 2025
Enrolling by invitation
Keywords
ClinConnect Summary
This study is checking whether a simple foot massage technique called myofascial release—using a tennis ball moved under the sole of the foot—can improve balance and overall quality of life for people with cancer who have nerve problems after chemotherapy. It especially includes adults aged 25 to 65 who have colorectal cancer, have completed standard chemotherapy, and have moderate to more noticeable peripheral neuropathy (nerve damage in the feet or hands). Eligible participants should have a Karnofsky Performance Status of 80 or higher (meaning they can do most daily activities with some effort), and they must not have skin sensitivity on the hands or feet, neuropathy from other causes, or bone/spine metastases, among other criteria.
If you participate, you would be randomly assigned to either receive the tennis-ball myofascial release or to a no-treatment control. Researchers will measure several outcomes, including balance tests (like standing on one leg and side-to-side reach), pain levels, sensation tests, and overall quality of life using standardized questionnaires. The study is taking place at Selçuk University in Konya, Turkey, led by Assist. Prof. Ülkü Saygılı, and aims to enroll about 50 people. At the moment, the trial is still enrolling, and results are not yet available.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Complaints of peripheral neuropathy among patients who have completed the standard chemotherapy treatment protocol due to colorectal cancer, entered the follow-up process and come to the outpatient clinic for routine control.
- • Registered to Selçuk University Faculty of Medicine Hospital Medical Oncology Polyclinic
- • Karnofsky Performance Scale must be 80 or above
- • Over 25 years old, under 65 years old
- • Presence of grade 2 or higher peripheral neuropathy,
- • Being conscious and cooperative
- • Verbal and written approval to participate in the study after an explanation about the study is made.
- Exclusion Criteria:
- • Having any skin sensitivity on hands and feet before
- • Refused to participate in the study after making a statement about the study
- • Development of peripheral neuropathy due to reasons other than chemotherapy \[tumor compression, nutritional disorders, infections or major systemic disease (diabetes mellitus, etc.)\]
- • Bone or spine metastases
About Selcuk University
Selçuk University is a prominent educational institution located in Turkey, recognized for its commitment to advancing medical research and clinical studies. As a clinical trial sponsor, Selçuk University leverages its extensive academic resources and expertise to conduct innovative research that aims to address significant healthcare challenges. The university fosters collaboration among researchers, healthcare professionals, and industry partners to facilitate the development of new therapies and improve patient outcomes. Through rigorous adherence to ethical standards and regulatory guidelines, Selçuk University strives to contribute to scientific knowledge and enhance the quality of care within the community and beyond.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Selçuklu, Konya, Turkey
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported